Israeli Cancer Support Chatbot Gets Top Marks From US Oncologists

Israeli startup Belong.Life says its AI chatbot dedicated to supporting cancer patients has received “high validation” in a survey by the American Society of Clinical Oncology (ASCO). 

The chatbot is able to provide oncology-specific, precise, comprehensive and empathetic answers to cancer patients’ challenges. It also communicates empathetically with users and retains a long-term memory of previous conversations, allowing multiple chat sessions.

The survey was carried out by eight senior oncologists who are affiliated with a number of top medical institutions. 

Dave was presented with 471 questions from cancer patients and their caregivers, and the bot’s responses were assessed by the oncologists for their relevance and helpfulness, as well as how closely they aligned with evidence-based medicine and current recommendations and guidelines. 

The eight oncologists found Dave to be 91.8 percent accurate, while just 1 percent of his responses were determined to be not at all helpful or relevant.

“This important validation evaluation, conducted by leading oncologists, supports the accuracy and reliability of an AI-powered Cancer Mentor in supporting the complex questions and needs of people diagnosed with cancer,” said Dr. Daniel Vorobiof, veteran oncologist and Chief Medical Director at Belong.Life.

“Patients and caregivers turning to Dave can rest assured that they are receiving valid information relevant to their personal medical situation. We are strongly encouraged by these excellent results as we continue exploring additional avenues to expand quality AI support to assist patients, caregivers and physicians alike.”